Drug Profile
Research programme: monoclonal antibody therapeutics - Tanabe Research Laboratories/Juno Therapeutics
Latest Information Update: 09 Mar 2018
Price :
$50
*
At a glance
- Originator Tanabe Research Laboratories USA; X-BODY BioSciences
- Developer Juno Therapeutics; Tanabe Research Laboratories USA
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 02 Jun 2015 X-BODY BioSciences has been acquired by Juno Therapeutics